Navamedic Valuation
Is 0FDB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0FDB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0FDB (NOK30.7) is trading below our estimate of fair value (NOK143.1)
Significantly Below Fair Value: 0FDB is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0FDB?
Key metric: As 0FDB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0FDB's PE Ratio? | |
|---|---|
| PE Ratio | 23.3x |
| Earnings | NOK 19.62m |
| Market Cap | NOK 457.47m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1x |
| Enterprise Value/EBITDA | 9.7x |
| PEG Ratio | 0.8x |
Price to Earnings Ratio vs Peers
How does 0FDB's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 24.2x | ||
EAH ECO Animal Health Group | 42.7x | 34.2% | UK£44.7m |
ANCR Animalcare Group | 32.1x | 15.8% | UK£148.5m |
HIK Hikma Pharmaceuticals | 19x | 12.8% | UK£4.3b |
C4XD C4X Discovery Holdings | 2.9x | -88.3% | UK£30.3m |
0FDB Navamedic | 23.3x | 29.6% | NOK 457.5m |
Price-To-Earnings vs Peers: 0FDB is good value based on its Price-To-Earnings Ratio (23.3x) compared to the peer average (24.2x).
Price to Earnings Ratio vs Industry
How does 0FDB's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 0FDB is expensive based on its Price-To-Earnings Ratio (23.3x) compared to the European Pharmaceuticals industry average (20.3x).
Price to Earnings Ratio vs Fair Ratio
What is 0FDB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 23.3x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 0FDB's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
0ILL
€62.90
7D
1.5%
1Y
14.6%
Formycon
€827.2m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€47.10
7D
4.0%
1Y
-23.5%
Regeneron Pharmaceuticals
US$79.4b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$748.39
7D
-1.7%
1Y
-6.3%